NovoCure Ltd Operating Income Loss

• NovoCure Ltd showed an increase of +9.8% in Operating Income Loss from 2024 to 2025.
• This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 13 years of available data (2013 to 2025), NovoCure Ltd's Operating Income Loss has declined by 138.6%.
• Historical annual values: Fiscal year 2025: -$153.80 million | Fiscal year 2024: -$170.50 million | Fiscal year 2023: -$232.87 million | Fiscal year 2022: -$89.52 million | Fiscal year 2021: -$44.33 million | Fiscal year 2020: $30.40 million | Fiscal year 2019: -$914.0 thousand | Fiscal year 2018: -$33.67 million | Fiscal year 2017: -$39.33 million | Fiscal year 2016: -$115.32 million | Fiscal year 2015: -$104.00 million | Fiscal year 2014: -$80.16 million | Fiscal year 2013: -$64.46 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026